215.37 Net Asset Value | -0.58% 1 Day | -1.84% Year-to-Date | Overall Morningstar Rating |
Health Style or Category | No Load Sales Expenses | 0.75% Expense Ratio | High Morningstar Risk Rating™ |
1 month | -6.11% | 3 years | -2.03% | |
3 months | -2.64% | 5 years | +14.39% | |
1 year | +15.08% | Since inception | +13.60% |
FBIOX | Category | |
---|---|---|
Performance 5-yr return | +14.39% | +14.29% |
Expense ratio | 0.75% | 1.30% |
Risk 5 year sharpe ratio | 0.68 | 0.92 |
Net assets | $8.6B | $3.0B |
Average market cap | $6.7B | $10.0B |
Average P/E | -- | 22.2 |
Portfolio turnover | 28% | 28% |
There are thousands of mutual funds to choose from. Get Money Magazine’s picks in all major categories.
Fund family | Fidelity Investments |
Fund manager & tenure | Rajiv Kaul / 12 Years |
Minimal initial investment | $2,500.00 |
Minimum IRA investment | $2,500.00 |
U.S. stock | 93.64% |
International stock | 3.64% |
Other | 2.11% |
Cash | 0.60% |
Fixed income | 0.00% |
Healthcare | 100.00% |
Business service | 0.00% |
Consumer goods | 0.00% |
Consumer service | 0.00% |
Energy | 0.00% |
ABBV AbbVie | 6.00% |
AMGN Amgen | 5.76% |
BIIB Biogen | 4.05% |
CELG Celgene | 3.47% |
VRTX Vertex Pharmaceuticals Inc | 3.25% |
ALXN Alexion Pharmaceuticals Inc | 2.20% |
GILD Gilead Sciences | 2.19% |
REGN Regeneron Pharmaceuticals | 2.04% |
ALNY Alnylam Pharmaceuticals Inc | 2.00% |
NBIX Neurocrine Biosciences Inc | 1.95% |